SACRAMENTO, Calif., April 21 /PRNewswire-USNewswire/ -- Tomato products may protect against inflammation. Such were the findings from a recent multi-center, randomized, controlled trial on the effects of processed tomatoes on vasodilatation and C-reactive protein in overweight and obese men and women, presented by one of the study researchers, Rose M Giordano, Ph.D. on April 19, 2009 at the Experimental Biology meeting held in New Orleans, La.
An immerging body of research suggests that inflammation may be a significant component in the development of chronic diseases such as cardiovascular disease, cancer, obesity, metabolic syndrome, type 2 diabetes, osteoporosis, periodontal disease, rheumatoid arthritis, neurological degenerative disorders, and inflammatory bowel disorders. There is growing interest in the role that diet may play in reducing inflammation in order to protect against such chronic diseases.
The regular consumption of tomato products has been consistently associated with a lower risk of several types of cancer and coronary heart disease. Using data from adults in the National Health and Nutrition Examination Survey (1999-2004), researchers recently found that consumption of processed tomatoes was associated with significantly lower serum C-reactive protein. C-reactive protein is a recognized biomarker of inflammation.
Scientists are intrigued with the array of nutrients such as vitamins A and C, fiber, potassium, beta-carotene, and lycopene that appear to work together in unison to provide health benefits. Particular interest has surrounded lycopene, a powerful antioxidant found abundantly in processed tomato products. Tomatoes, the second most popular vegetable in the country, represent an excellent opportunity to ward off chronic disease. Since processed tomato products are both economical and easily adaptable to a variety of cultural diets, their health benefits warrant further investigation.
Given the potential for tomato products to protect against chronic disease, researchers from the University of California, Davis, National Center for Food Safety & Technology in Illinois, and Penn State University investigated the effects of processed tomato products on vasodilatation (another target for lowering disease through dietary strategies) and C-reactive protein on overweight and obese men and women. Within the diets of 56 free-living individuals participating in the study, processed tomato products or non-tomato products were matched in calories, sodium, and sugar content. All of the test subjects consumed a low-tomato diet for three weeks followed by either a six week high-tomato diet or low-tomato diet. At six weeks, the subjects were assessed as to the response of tomato after eating a high-fat meal. Compared with the low-tomato group, the high-tomato group experienced a C-reactive protein level that was lower in response to the high-fat meal. High-tomato intake was also associated with increased mean vessel diameter, but flow mediated vasodilatation was not different, possibly related to the BMI of subjects. The researchers concluded that processed tomatoes provide a protective role on inflammation, but increasing adiposity may negate the benefits of the high-tomato diet on endothelial function.
Researchers in the study include Rose M Giordano, Tissa Kappagoda, Mandeep Cheema, Jack Cappozzo, Yumei Cao, Penny Kris-Etherton, and Britt Burton-Freeman. The study was sponsored by the Tomato Products Wellness Council (www.tomatowellness.com).
If you would like additional information or would like to schedule an interview, please contact Rodger Wasson at (831) 254-5405 or email@example.com.
Telephone: (831) 254-5405
Related medicine technology :1
|SOURCE Tomato Products Wellness Council|
Copyright©2009 PR Newswire.
All rights reserved
. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer2
. Evidence Lacking in Multivitamin Study of Womens Risk of Cancer, Heart Disease or Death, Says Natural Products Association3
. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)4
. Clinical Lab Products Magazine Features Biomoda5
. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)6
. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products7
. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model8
. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 7439
. Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives10
. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder11
. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis